Sentence: Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['cetuximab', 'mitoxantrone', 'prednisone'], 'is_context_needed': True}]